<DOC>
	<DOC>NCT01541423</DOC>
	<brief_summary>This observational (non-interventional) study is being conducted to characterize the safety and use of CINRYZE in routine clinical practice when administered for (1) routine prevention of angioedema attacks, (2) pre-procedure prevention of angioedema attacks, and/or (3) treatment of angioedema attacks.</brief_summary>
	<brief_title>A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas, Hereditary</mesh_term>
	<criteria>Inclusion Criteria All patients must: Have a diagnosis of HAE and be receiving CINRYZE for prevention or treatment of angioedema attacks Provide written informed consent/assent in compliance with applicable countryspecific and local regulations Exclusion Criteria All patients must not: Be receiving CINRYZE in an investigational study Be receiving another HAE therapy as part of a clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>